High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis

Azim, Hatem A.; Santoro, Luigi; Bociek, R. Gregory; Gandini, Sara; Abdel-Malek, Raafat

doi:10.1093/annonc/mdp425

Cited by 14 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dosages regularly used in chemotherapeutic protocols for horses are extrapolated from other species, and cyclophosphamide dose optimization has not been reported in horses. Dose intensity refers to the dose of active drug over time, and multiple studies in humans and animals with cancer have shown that increasing chemotherapeutic dose intensity correlates with increased antitumor effect . Chemotherapeutic drug dose escalation is a strategy of gradual dose increases with careful monitoring for toxicity, utilized to determine the highest tolerated dose and thereby achieve higher dose intensity and maximum efficacy.…”

Section: Discussionmentioning

confidence: 99%

Retrospective evaluation of clinical outcome after chemotherapy for lymphoma in 15 equids (1991‐2017)

Luethy

Frimberger²,

Bedenice

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Prognosis associated with lymphoma in horses is poorly characterized, and treatment is often palliative. Long‐term outcome after chemotherapy for horses with lymphoma is not well documented. Objective To report long‐term outcome of horses with lymphoma treated with chemotherapy. Animals Fifteen equids. Methods Retrospective case series. Medical record search and call for cases on the ACVIM listserv for horses treated with chemotherapy for lymphoma. Results Fifteen cases with adequate data were identified. Complete remission was achieved in 5 horses (33.3%), partial response was achieved in 9 equids (60%), and stable disease was achieved in 1 horse. Overall response rate was 93.3% (14/15). Overall median survival time was 8 months (range, 1‐46 months). Nine horses experienced a total of 14 adverse effects attributable to chemotherapy. Adverse effects were graded according to the Veterinary Cooperative Oncology Group common terminology criteria for adverse events grading system (grade 1 alopecia, n = 2; grade 1 neutropenia, n = 2; grade 1 lymphopenia, n = 3; grade 1 lethargy, n = 1; grade 2 neurotoxicity, n = 1; grade 2 colic, n = 1; grade 1 hypersensitivity, n = 1; grade 2 hypersensitivity, n = 2; grade 5 hypersensitivity, n = 1). Higher grade adverse effects most commonly were associated with doxorubicin administration (n = 4), including 1 horse that died 18 hours post‐administration. Conclusions and Clinical Importance Chemotherapy can be used successfully for treatment of horses with lymphoma. Adverse effects, most commonly mild, occurred in approximately two‐thirds of treated horses.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective evaluation of clinical outcome after chemotherapy for lymphoma in 15 equids (1991‐2017)

Luethy

Frimberger²,

Bedenice

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Hodgkin lymphomas are essentially curable with standard chemotherapy treatments of doxorubicin, bleomycin, vinblastin, and darcarbazine, but improvements can still be made in reducing off‐target side effects 233. Non‐Hodgkin lymphomas have historically been treated with standard chemotherapy of cyclophosphamide, doxorubicin, vincristine, and prednisone 234. Antibody based therapy with Rituximab has been shown to improve response in both first‐line treatments and in patients with relapsed or refractory cancers 235.…”

Section: Applications Of Targeted Therapiesmentioning

confidence: 99%

Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery Across Biological Barriers

2011

View full text Add to dashboard Cite

Cancer nanotheranostics aims to combine imaging and therapy of cancer through use of nanotechnology. The ability to engineer nanomaterials to interact with cancer cells at the molecular level can significantly improve the effectiveness and specificity of therapy to cancers that are currently difficult to treat. In particular, metastatic cancers, drug-resistant cancers, and cancer stem cells impose the greatest therapeutic challenge that requires targeted therapy to treat effectively. Targeted therapy can be achieved with appropriate designed drug delivery vehicles such as nanoparticles, adult stem cells, or T cells in immunotherapy. In this article, we first review the different types of materials commonly used to synthesize nanotheranostic particles and their use in imaging. We then discuss biological barriers that these nanoparticles encounter and must bypass to reach the target cancer cells, including the blood, liver, kidneys, spleen, and particularly the blood-brain barrier. We then review how nanotheranostics can be used to improve targeted delivery and treatment of cancer cells using nanoparticles, adult stem cells, and T cells in immunotherapy. Finally, we discuss development of nanoparticles to overcome current limitations in cancer therapy.

show abstract

“…The outcome of this study determined that doxorubicin should be used for the treatment of aggressive non-Hodgkin's lymphomas and dose intensity of doxorubicin was a key factor in predicting patient survival. Further, a meta-analysis of published randomized controlled trials comparing chemotherapy regimens incorporating doxorubicin at a high dose with standard CHOP therapy was conducted and their conclusions were consistent with the Kwak and colleagues study [35]. Altogether, levels of TOP2A in BLs are elevated relative to immortalized B cells and that high dose doxorubicin in addition to standard CHOP therapy may improve Burkitt's lymphoma patient outcome through TOP2A mediated doxorubicin response.…”

Section: Discussionmentioning

confidence: 53%

RNA CoMPASS: A Dual Approach for Pathogen and Host Transcriptome Analysis of RNA-Seq Datasets

Strong

Lacey

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

High-throughput RNA sequencing (RNA-seq) has become an instrumental assay for the analysis of multiple aspects of an organism's transcriptome. Further, the analysis of a biological specimen's associated microbiome can also be performed using RNA-seq data and this application is gaining interest in the scientific community. There are many existing bioinformatics tools designed for analysis and visualization of transcriptome data. Despite the availability of an array of next generation sequencing (NGS) analysis tools, the analysis of RNA-seq data sets poses a challenge for many biomedical researchers who are not familiar with command-line tools. Here we present RNA CoMPASS, a comprehensive RNA-seq analysis pipeline for the simultaneous analysis of transcriptomes and metatranscriptomes from diverse biological specimens. RNA CoMPASS leverages existing tools and parallel computing technology to facilitate the analysis of even very large datasets. RNA CoMPASS has a web-based graphical user interface with intrinsic queuing to control a distributed computational pipeline. RNA CoMPASS was evaluated by analyzing RNA-seq data sets from 45 B-cell samples. Twenty-two of these samples were derived from lymphoblastoid cell lines (LCLs) generated by the infection of naïve B-cells with the Epstein Barr virus (EBV), while another 23 samples were derived from Burkitt's lymphomas (BL), some of which arose in part through infection with EBV. Appropriately, RNA CoMPASS identified EBV in all LCLs and in a fraction of the BLs. Cluster analysis of the human transcriptome component of the RNA CoMPASS output clearly separated the BLs (which have a germinal center-like phenotype) from the LCLs (which have a blast-like phenotype) with evidence of activated MYC signaling and lower interferon and NF-kB signaling in the BLs. Together, this analysis illustrates the utility of RNA CoMPASS in the simultaneous analysis of transcriptome and metatranscriptome data. RNA CoMPASS is freely available at http://rnacompass.sourceforge.net/.

show abstract

High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis

Abstract: High DI doxorubicin based should be considered in patients with aggressive NHL.

Cited by 14 publications

References 25 publications

Retrospective evaluation of clinical outcome after chemotherapy for lymphoma in 15 equids (1991‐2017)

Retrospective evaluation of clinical outcome after chemotherapy for lymphoma in 15 equids (1991‐2017)

Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery Across Biological Barriers

RNA CoMPASS: A Dual Approach for Pathogen and Host Transcriptome Analysis of RNA-Seq Datasets

Contact Info

Product

Resources

About